On the Frontlines of Psoriasis

Host: Steve Jackson, PharmD Psoriasis is more than a skin disease—it's a chronic, immune-mediated condition associated with significant psychiatric and psychosocial comorbidities, including depression, anxiety, and suicidal ideation. In this conversation with Dr. Steve Jackson, Dr. Margo Gkini shares practical strategies for screening and identifying mental health challenges in these patients. Dr....

Guest: Mio Nakamura, MD, MS Host: Steve Jackson, PharmD Psoriasis is more than a visible skin condition; it carries a profound psychological and emotional burden that can disrupt patients’ quality of life. In this conversation with Dr. Steve Jackson, Dr. Mio Nakamura shares practical insights on recognizing mental health impacts, assessing patient wellbeing beyond clinical severity, and integratin...

Host: Ryan Quigley Guest: Jenny Murase, MD Evolving insights into Th1-, Th2-, and Th17-driven inflammation are reshaping the diagnosis and management of patients presenting with mixed psoriasis subtypes. Ryan Quigley sits down with Dr. Jenny Murase to learn more about practical approaches to personalized treatment planning, common clinical pitfalls, and emerging strategies. Dr. Murase is the Found...

Host: Ryan Quigley Guest: Steven R. Feldman, MD, PhD In psoriasis management, patient adherence is a persistent challenge, especially with topical therapies for mild involvement. Ryan Quigley sits down with Dr. Steve Feldman to explore evidence-based, real-world strategies to support these patients and promote long-term success. Dr. Feldman is a professor of dermatology, pathology, and public heal...

Guest: Christopher Bunick, MD, PhD, FAAD Host: Ryan Quigley With high selectivity, durable response, and once-daily dosing, next-generation TYK2 inhibitors offer a promising oral option for patients with moderate-to-severe plaque psoriasis. Ryan Quigley sits down with Dr. Christopher Bunick, Associate Professor of Dermatology and Translational Biomedicine at Yale University School of Medicine, to...

Guest: Peter Lio, MD Host: Ryan Quigley Flare patterns, patient concerns, and growing research have brought diet to the forefront of psoriasis care. Tune in as Dr. Peter Lio reviews the strongest evidence behind weight management, gluten sensitivity, and anti-inflammatory nutrition, offering clarity on how diet can support—though not replace—primary treatments. Dr. Lio is a Clinical Assistant Prof...

New research highlights what patients with psoriasis really want to know about family planning and pregnancy—and when they want to hear it. Discover how proactively addressing these topics can close communication gaps, improve outcomes, and empower patients during this critical life stage with host Ryan Quigley and Ms. Liana Barenbrug, a PhD candidate at Radboud University Medical Center in the Ne...

Host: Ryan Quigley Guest: Michael Greenberg, MD A patient’s inner dialogue—especially negative self-talk—can influence their perception of disease, adherence to treatment, and emotional wellbeing. Ryan Quigley sits down with Dr. Michael Greenberg, a dermatologist at the Illinois Dermatology Institute, as he shares observations from his own practice, highlighting how recognizing subtle emotional cu...

Guest: Audrey Bui, DO Genetic insights are reshaping how we understand the development and comorbidities of psoriasis, as well as treatment response in patients. Hear Dr. Audrey Bui discuss how genetic variants influence risks for certain conditions, how they may predict response to therapies like methotrexate, ustekinumab, and IL-17 inhibitors, and how integrating genetic markers into clinical ca...

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Joel M. Gelfand, MD, MSCE, FAAD Guest: Michael S. Garshick, MD Inflammatory skin diseases like psoriasis don’t just affect the skin—they can often reflect broader cardiovascular risks. Given the overlap between dermatology and cardiology, knowing how to spot warning signs early and what steps to take during routine visits is key to compr...

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Joel M. Gelfand, MD, MSCE, FAAD Guest: Valerie Harrison, PhD Home-based narrowband UVB phototherapy may offer a more accessible and effective option for managing psoriasis, as shown by the results of a recent study. With benefits like improved adherence, lower costs, and greater accessibility, this approach offers a compelling alternative for patient...

Guest: Joe K. Tung, MD, MBA Psoriasis affects nearly eight million adults in the US, but its impact isn’t felt equally; significant disparities in diagnosis exist across race, ethnicity, and socioeconomic status. Join Dr. Joe Tung as he discusses his recent analysis of data from the National Health Interview Survey, in which he explored the most affected patient populations, the potential for unde...

Guest: Andrew Blauvelt, MD, MBA From novel oral therapies to advancements in biologic injections, the treatment landscape for psoriasis is rapidly evolving. Here to share his insights on how these new treatment strategies could improve efficacy, reduce safety concerns, and even make once-yearly biologic dosing a reality is Dr. Andrew Blauvelt. Dr. Blauvelt is a dermatologist and clinical researche...

Guest: Andrew Blauvelt, MD, MBA While systemic therapies like deucravacitinib have previously only been recommended for patients with moderate-to-severe plague psoriasis, it may be worth questioning whether body surface area alone is enough to dictate its use. Learn when scalp psoriasis may call for systemic therapies with Dr. Andrew Blauvelt, a dermatologist and clinical researcher with a focus o...

Guest: Philip J. Mease, MD Psoriasis is more than just a skin condition—it can significantly impact a patient’s relationships, daily functioning, and overall quality of life. Tune in to hear Dr. Philip J. Mease discuss the multidimensional nature of psoriasis and the importance of a holistic approach to care. Dr. Mease is the Director of Rheumatology Research at Providence Swedish Medical Center a...

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Joel M. Gelfand, MD, MSCE Researchers speculate that the Mediterranean Diet may have benefits for psoriasis patients because of its anti-inflammatory effects. In fact, a recent study has been examining the relationship between the Mediterranean Diet and factors like skin health, quality of life, and markers of inflammation in the blood. Join Dr. Joel...

Guest: Robert Gniadecki, MD A recent retrospective study using the Alberta Health Services Data Repository of Reporting found that patients with psoriasis had a significantly lower lifespan than a control group of patients with a comparable health profile. Join Dr. Robert Gniadecki, Professor and Director of the Division of Dermatology at the University of Alberta, as he dives into this data and e...

Guest: Andrew Blauvelt, MD, MBA As the only FDA-designated selective TYK2 inhibitor, deucravacitinib has emerged as a potential therapeutic option for scalp psoriasis. And after analyzing its impacts in a phase III clinical trial, it has continued to show promise in terms of both efficacy and safety. Hear more about deucravacitinib and how it compares to alternate options like JAK inhibitors from...

Guest: Atul A. Deodhar, MD, MRCP Managing psoriasis, psoriatic arthritis, and axial spondyloarthritis with ixekizumab may cause adverse effects in patients. That’s why a recent research review further investigated the safety of this treatment over time, analyzing data from 25 clinical trials and noting common side effects. Learn more about ixekizumab’s long-term use with Dr. Atul Deodhar, the lead...

Guest: Philip J. Mease, MD A recent study led by Dr. Philip J. Mease examined the factors contributing to biologic therapy switching among patients with psoriasis and psoriatic arthritis. Using data from the CorEvitas Psoriasis Registry, the study identified key drivers, including high Psoriasis Area and Severity Index (PASI) scores, poor quality of life, and significant joint pain. Tune in to lea...

Host: Raj Chovatiya, MD, PhD Guest: Tina Bhutani, MD, MAS Oftentimes patients with skin of color are diagnosed with psoriasis at a later stage than Caucasian patients. There are also disparities in access to treatment and education. According to a recent study, some patients with skin of color were less willing to use certain medications to treat their psoriasis. To learn more, join Dr. Raj Chovat...

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Taylor Dickerson, MD According to a recent study, patients with skin of color waited three times longer to be formally diagnosed with psoriasis and were almost four times more likely to be biopsied compared to non-Hispanic patients. And as a result, these patients were more likely to present with severe disease, greatly impacting their overall qualit...

Host: Raj Chovatiya, MD, PhD Guest: Steven R. Feldman, MD, PhD According to recent studies, only about 50 percent of psoriasis patients are adherent to topical medications by the end of an eight-week treatment period. This can have a significant impact on a patient’s overall quality of life and outcomes, which is why Dr. Raj Chovatiya speaks with Dr. Steven Feldman about strategies to improve psor...

Host: Raj Chovatiya, MD, PhD Guest: Jason E. Hawkes, MD, MS, FAAD There are a few key points that dermatologists need to keep at the forefront of conversations to help bridge education gaps around psoriasis. One is to try and eliminate burdens that are deterring practitioners in dermatology from using highly effective and very safe medications. To learn more on how we can have a positive impact on...

Guest: Shari Lipner, MD A recent study was conducted looking at initial therapies for newly diagnosed psoriasis patients by race. Prior studies have shown differences by race in terms of emerging treatments for different dermatological diseases, which have also shown differential biologic treatments based on race. To learn about the findings and how we can help fill this gap, join Dr. Shari Lipner...